NCT00023855 2019-12-13
PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors
University of Wisconsin, Madison
Phase 1 Completed
Clinical Trials
15 trialsNCT00290680 2018-04-10
Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors
Medical University of South Carolina
Phase 1 Completed
NCT00541359 2017-08-09
Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
City of Hope Medical Center
Phase 1 Completed
NCT02220049 2016-03-25
VELDAY
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT01497626 2016-02-17
Lapatinib and Bortezomib in Patients With Advanced Malignancies
Georgetown University
Phase 1 Terminated
NCT00021216 2015-04-15
Bortezomib in Treating Children With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00720148 2014-08-26
A Phase I Trial of Bortezomib and Sunitinib
Emory University
Phase 1 Completed
NCT00227513 2014-02-24
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00030368 2013-06-04
Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00500422 2013-02-13
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00027898 2013-02-07
Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00066625 2013-02-01
Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00068484 2013-02-01
A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies
National Cancer Institute (NCI)
Phase 1 Completed
NCT00028587 2013-01-16
PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00064636 2005-06-24
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Millennium Pharmaceuticals, Inc.
Phase 1 Terminated